Literature DB >> 23435425

ELF3 is a repressor of androgen receptor action in prostate cancer cells.

A Shatnawi1, J D Norris2, C Chaveroux1, J S Jasper2, A B Sherk2, D P McDonnell2, V Giguère3.   

Abstract

The androgen receptor (AR) has a critical role in the development and progression of prostate cancer (PC) and is a major therapeutic target in this disease. The transcriptional activity of AR is modulated by the coregulators with which it interacts, and consequently deregulation of cofactor expression and/or activity impacts the expression of genes whose products can have a role in PC pathogenesis. Here we report that E74-like factor 3 (ELF3), a member of the ETS family of transcription factors, is a repressor of AR transcriptional activity. Exogenous expression of ELF3 represses AR transcriptional activity when assessed using reporter-based transfection assays or when evaluated on endogenous AR target genes. Conversely, ELF3 knock down increases the AR transcriptional activity. Biochemical dissection of this activity indicates that it results from the physical interaction between ELF3 and AR and that this interaction inhibits the recruitment of AR to specific androgen response elements within target gene promoters. Significantly, we observed that depletion of ELF3 expression in LNCaP cells promotes cell migration, whereas increased ELF3 expression severely inhibits tumor growth in vitro and in a mouse xenograft model. Taken together, these results suggest that modulation of ELF3 expression and/or AR/ELF3 interaction may have utility in the treatment of PC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23435425      PMCID: PMC4103030          DOI: 10.1038/onc.2013.15

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  40 in total

Review 1.  Minireview: nuclear receptor and coregulator proteomics--2012 and beyond.

Authors:  Bert W O'Malley; Anna Malovannaya; Jun Qin
Journal:  Mol Endocrinol       Date:  2012-06-28

2.  PTP1B is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer.

Authors:  Laurent Lessard; David P Labbé; Geneviève Deblois; Louis R Bégin; Serge Hardy; Anne-Marie Mes-Masson; Fred Saad; Lloyd C Trotman; Vincent Giguère; Michel L Tremblay
Journal:  Cancer Res       Date:  2012-01-26       Impact factor: 12.701

3.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.

Authors:  Jindan Yu; Jianjun Yu; Ram-Shankar Mani; Qi Cao; Chad J Brenner; Xuhong Cao; Xiaoju Wang; Longtao Wu; James Li; Ming Hu; Yusong Gong; Hong Cheng; Bharathi Laxman; Adaikkalam Vellaichamy; Sunita Shankar; Yong Li; Saravana M Dhanasekaran; Roger Morey; Terrence Barrette; Robert J Lonigro; Scott A Tomlins; Sooryanarayana Varambally; Zhaohui S Qin; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

4.  Interplay between proximal and distal promoter elements is required for squamous differentiation marker induction in the bronchial epithelium: role for ESE-1, Sp1, and AP-1 proteins.

Authors:  Sekhar P M Reddy; Hue Vuong; Pavan Adiseshaiah
Journal:  J Biol Chem       Date:  2003-04-07       Impact factor: 5.157

5.  R5020 and RU486 act as progesterone receptor agonists to enhance Sp1/Sp4-dependent gene transcription by an indirect mechanism.

Authors:  Aymen Shatnawi; Thuyet Tran; Manohar Ratnam
Journal:  Mol Endocrinol       Date:  2006-12-27

6.  Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence.

Authors:  Philip Kahl; Lucia Gullotti; Lukas Carl Heukamp; Susanne Wolf; Nicolaus Friedrichs; Roland Vorreuther; Gerold Solleder; Patrick J Bastian; Jörg Ellinger; Eric Metzger; Roland Schüle; Reinhard Buettner
Journal:  Cancer Res       Date:  2006-12-01       Impact factor: 12.701

Review 7.  Androgen receptor-cofactor interactions as targets for new drug discovery.

Authors:  Ching-yi Chang; Donald P McDonnell
Journal:  Trends Pharmacol Sci       Date:  2005-05       Impact factor: 14.819

8.  The epithelial-specific ETS transcription factor ESX/ESE-1/Elf-3 modulates breast cancer-associated gene expression.

Authors:  Kristin L Eckel; John J Tentler; Gerald J Cappetta; Scott E Diamond; Arthur Gutierrez-Hartmann
Journal:  DNA Cell Biol       Date:  2003-02       Impact factor: 3.311

9.  ESE-1 is a novel transcriptional mediator of inflammation that interacts with NF-kappa B to regulate the inducible nitric-oxide synthase gene.

Authors:  S Rudders; J Gaspar; R Madore; C Voland; F Grall; A Patel; A Pellacani; M A Perrella; T A Libermann; P Oettgen
Journal:  J Biol Chem       Date:  2000-10-17       Impact factor: 5.157

10.  Mitochondrial localization, ELK-1 transcriptional regulation and growth inhibitory functions of BRCA1, BRCA1a, and BRCA1b proteins.

Authors:  Anna W Maniccia; Catherine Lewis; Nurjahan Begum; Jingyao Xu; Jianqi Cui; Galina Chipitsyna; Kartik Aysola; Vaishali Reddy; Ganapathy Bhat; Yasuo Fujimura; Beric Henderson; E Shyam P Reddy; Veena N Rao
Journal:  J Cell Physiol       Date:  2009-06       Impact factor: 6.384

View more
  12 in total

1.  Master transcription factors form interconnected circuitry and orchestrate transcriptional networks in oesophageal adenocarcinoma.

Authors:  Li Chen; Moli Huang; Jasmine Plummer; Jian Pan; Yan Yi Jiang; Qian Yang; Tiago Chedraoui Silva; Nicole Gull; Stephanie Chen; Ling Wen Ding; Omer An; Henry Yang; Yulan Cheng; Jonathan W Said; Ngan Doan; Winand Nm Dinjens; Kevin M Waters; Richard Tuli; Simon A Gayther; Samuel J Klempner; Benjamin P Berman; Stephen J Meltzer; De-Chen Lin; H Phillip Koeffler
Journal:  Gut       Date:  2019-08-13       Impact factor: 23.059

2.  Profiling of differentially expressed genes in cadmium-induced prostate carcinogenesis.

Authors:  Venkatesh Kolluru; Ashish Tyagi; Balaji Chandrasekaran; Chendil Damodaran
Journal:  Toxicol Appl Pharmacol       Date:  2019-05-11       Impact factor: 4.219

3.  Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation.

Authors:  Marie-Claude Gingras; Kyle R Covington; David K Chang; Lawrence A Donehower; Anthony J Gill; Michael M Ittmann; Chad J Creighton; Amber L Johns; Eve Shinbrot; Ninad Dewal; William E Fisher; Christian Pilarsky; Robert Grützmann; Michael J Overman; Nigel B Jamieson; George Van Buren; Jennifer Drummond; Kimberly Walker; Oliver A Hampton; Liu Xi; Donna M Muzny; Harsha Doddapaneni; Sandra L Lee; Michelle Bellair; Jianhong Hu; Yi Han; Huyen H Dinh; Mike Dahdouli; Jaswinder S Samra; Peter Bailey; Nicola Waddell; John V Pearson; Ivon Harliwong; Huamin Wang; Daniela Aust; Karin A Oien; Ralph H Hruban; Sally E Hodges; Amy McElhany; Charupong Saengboonmee; Fraser R Duthie; Sean M Grimmond; Andrew V Biankin; David A Wheeler; Richard A Gibbs
Journal:  Cell Rep       Date:  2016-01-21       Impact factor: 9.423

Review 4.  Moonlighting proteins in cancer.

Authors:  Kyung-Won Min; Seong-Ho Lee; Seung Joon Baek
Journal:  Cancer Lett       Date:  2015-10-20       Impact factor: 8.679

5.  ETS transcription factor ELF3 (ESE-1) is a cell cycle regulator in benign and malignant prostate.

Authors:  Leanne K Archer; Fiona M Frame; Hannah F Walker; Alastair P Droop; Georgina L K McDonald; Samuel Kucko; Daniel M Berney; Vincent M Mann; Matthew S Simms; Norman J Maitland
Journal:  FEBS Open Bio       Date:  2022-05-06       Impact factor: 2.792

6.  Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers.

Authors:  Lourdes Mengual; Juan José Lozano; Mercedes Ingelmo-Torres; Laura Izquierdo; Mireia Musquera; María José Ribal; Antonio Alcaraz
Journal:  BMC Cancer       Date:  2016-02-09       Impact factor: 4.430

7.  Unique transcriptional signatures of sleep loss across independently evolved cavefish populations.

Authors:  Suzanne E McGaugh; Courtney N Passow; James Brian Jaggard; Bethany A Stahl; Alex C Keene
Journal:  J Exp Zool B Mol Dev Evol       Date:  2020-04-29       Impact factor: 2.656

8.  Transcriptomic analysis of castration, chemo-resistant and metastatic prostate cancer elucidates complex genetic crosstalk leading to disease progression.

Authors:  Sayani Mukherjee; C Sudandiradoss
Journal:  Funct Integr Genomics       Date:  2021-06-29       Impact factor: 3.410

9.  Elf3 drives β-catenin transactivation and associates with poor prognosis in colorectal cancer.

Authors:  J-L Wang; Z-F Chen; H-M Chen; M-Y Wang; X Kong; Y-C Wang; T-T Sun; J Hong; W Zou; J Xu; J-Y Fang
Journal:  Cell Death Dis       Date:  2014-05-29       Impact factor: 8.469

10.  ELF3 is an antagonist of oncogenic-signalling-induced expression of EMT-TF ZEB1.

Authors:  D Liu; Y Skomorovska; J Song; E Bowler; R Harris; M Ravasz; S Bai; M Ayati; K Tamai; M Koyuturk; X Yuan; Z Wang; Y Wang; R M Ewing
Journal:  Cancer Biol Ther       Date:  2018-08-27       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.